Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MVA-based SARS-CoV-2 vaccine candidates encoding different spike protein conformations induce distinct early transcriptional responses which may impact subsequent adaptive immunity.
Grewe I, Friedrich M, Dieck ML, Spohn M, Ly ML, Krähling V, Mayer L, Mellinghoff SC, Rottstegge M, Kraemer R, Volz A, Becker S, Fathi A, Dahlke C, Weskamm LM, Addo MM. Grewe I, et al. Among authors: volz a. Front Immunol. 2024 Dec 19;15:1500615. doi: 10.3389/fimmu.2024.1500615. eCollection 2024. Front Immunol. 2024. PMID: 39749328 Free PMC article. Clinical Trial.
Scent dogs identify SARS-CoV-2-infections in respiratory samples from experimentally infected ferrets and hamsters-a pilot study.
Schulz C, Twele F, Meller S, Ten Hagen NA, Pilchová V, Wirz K, Clever S, Meyer Zu Natrup C, Volz A, von Köckritz-Blickwede M, Volk HA. Schulz C, et al. Among authors: volz a. Front Med (Lausanne). 2024 Dec 9;11:1476300. doi: 10.3389/fmed.2024.1476300. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39717173 Free PMC article.
A Brighton collaboration standardized template with key considerations for a benefit/risk assessment for a viral vector vaccine based on a non-replicating modified vaccinia virus Ankara viral vector.
Link EK, Tscherne A, Sutter G, Smith ER, Gurwith M, Chen RT, Volz A; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO; ex-V3SWG). Link EK, et al. Among authors: volz a. Vaccine. 2025 Jan 1;43(Pt 1):126521. doi: 10.1016/j.vaccine.2024.126521. Epub 2024 Nov 28. Vaccine. 2025. PMID: 39612556 Free article. Review.
208 results